Methods and compositions for treating drug resistance in cancer
Disclosed herein are compositions and methods for treating cancer. Further provided herein are compositions and methods for reducing, inhibiting, or preventing resistance of cancer to tyrosine kinase inhibitors. The methods may include administering an anti-resistance agent such as a CYP51A1 inhibitor or an agonist of miRNA-764 (SEQ ID NO: 4) to a subject. A tyrosine kinase inhibitor may also be administered to the subject in addition to the anti-resistance agent.
1. A method of treating cancer in a subject, the method comprising administering to the subject a tyrosine kinase inhibitor and an anti-resistance agent, wherein the anti-resistance agent comprises a CYP51A1 inhibitor, or an agonist of SEQ ID NO: 4 (miRNA-764), or a combination thereof, and wherein the cancer is a tyrosine kinase inhibitor-resistant cancer.
2. The method of claim 1 , wherein the tyrosine kinase inhibitor and the anti-resistance agent are co-administered to the subject.
3. The method of claim 1 , wherein the tyrosine kinase inhibitor is administered to the subject prior to the anti-resistance agent.
4. The method of claim 1 , wherein the anti-resistance agent is administered to the subject prior to the tyrosine kinase inhibitor.
5. A method of treating cancer in a subject undergoing treatment with a tyrosine kinase inhibitor, the method comprising administering to the subject an anti-resistance agent, wherein the anti-resistance agent comprises a CYP51A1 inhibitor, or an agonist of SEQ ID NO: 4 (miRNA-764), or a combination thereof, and wherein the cancer is a tyrosine kinase inhibitor-resistant cancer.
6. The method of claim 1 , wherein the cancer comprises non-small cell lung cancer (NSCLC).
7. The method of claim 1 , wherein acquired drug resistance to the tyrosine kinase inhibitor is decreased or prevented.
8. The method of claim 7 , wherein tyrosine kinase inhibitor resistance is decreased at least 2-fold.
9. The method of claim 7 , wherein tyrosine kinase inhibitor resistance is decreased at least 5-fold.
10. The method of claim 7 , wherein the activity of the tyrosine kinase inhibitor is increased at least 2-fold.
11. The method of claim 7 , wherein the activity of the tyrosine kinase inhibitor is increased at least 5-fold.
12. The method of claim 1 , wherein the tyrosine kinase inhibitor comprises lapatinib.